Current Vascular Pharmacology

Editor-in-Chief:

Dimitri P. Mikhailidis  
Academic Head, Department of Clinical Biochemistry
Royal Free Hospital Campus
University College London Medical School
University College London (UCL)
Pond Street, London, NW3 2QG
UK

Back

Become EABM
Become Reviewer



Meet Our Editorial Board Member free to download

Volume:16   Issue: 3
Pp: 205-205
Aurelio Leone
DOI: 10.2174/157016111603180326112112



Editorial: Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis: An Epidemic that will Boost the Incidence of Cardiovascular Morbidity and Mortality free to download

Volume:16   Issue: 3
Pp: 206-208
Vasilios G. Athyros and Michael Doumas
DOI: 10.2174/157016111603180326112541



NAFLD-NASH: An Under-Recognized Epidemic

Volume:16   Issue: 3
Pp: 209-213
Joseph Jennings, Charles Faselis and Michael D. Yao*
DOI: 10.2174/1570161115666170622074007




Nonalcoholic Fatty Liver Disease vs. Nonalcoholic Steatohepatitis: Pathological and Clinical Implications

Volume:16   Issue: 3
Pp: 214-218
Chrysoula Boutari*, Petros Lefkos, Vasilios G. Athyros, Asterios Karagiannis and Konstantinos Tziomalos
DOI: 10.2174/1570161115666170621075157




Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome?

Volume:16   Issue: 3
Pp: 219-227
Niki Katsiki, Pablo Perez-Martinez, Panagiotis Anagnostis, Dimitri P. Mikhailidis* and Asterios Karagiannis
DOI: 10.2174/1570161115666170621075619




A Critical Approach of Guideline Therapeutic Recommendations for NAFLD

Volume:16   Issue: 3
Pp: 228-238
Dragan B. Djordjevic, Marija Zdravkovic, Aleksandar Nagorni, Athanasios Manolis, Costas Tsioufis and Dragan Lovic*
DOI: 10.2174/1570161115666170621080228




Lifestyle Modifications in Non-Alcoholic Fatty Liver Disease and Non- Alcoholic Steatohepatitis

Volume:16   Issue: 3
Pp: 239-245
Konstantinos Stavropoulos, Konstantinos Imprialos, Andreas Pittaras, Charles Faselis, Puneet Narayan and Peter Kokkinos*
DOI: 10.2174/1570161115666170621080835




Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk

Volume:16   Issue: 3
Pp: 246-253
Vasilios G. Athyros*, Chrysa Boutari, Konstantinos Stavropoulos, Panagiotis Anagnostis, Konstantinos P. Imprialos, Michael Doumas and Asterios Karagiannis
DOI: 10.2174/1570161115666170621082910




The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options?

Volume:16   Issue: 3
Pp: 254-268
Marianna Papademetriou, Vasilios G. Athyros, Eleni Geladari, Michael Doumas, Costas Tsioufis and Vasilios Papademetriou*
DOI: 10.2174/1570161115666170621081638




Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?

Volume:16   Issue: 3
Pp: 269-275
Paschalis Paschos, Vasilios G. Athyros, Achilleas Tsimperidis, Anastasia Katsoula, Nikolaos Grammatikos and Olga Giouleme*
DOI: 10.2174/1570161115666170621082237




Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease

Volume:16   Issue: 3
Pp: 276-288
Konstantinos Imprialos, Konstantinos Stavropoulos, Sofia Bouloukou, Georgios Kerpiniotis, Asterios Karagiannis and Michael Doumas*
DOI: 10.2174/1570161115666170621083744




Vitamin D Levels in Middle-Aged Patients with Obstructive Sleep Apnoea Syndrome

Volume:16   Issue: 3
Pp: 289-297
K. Archontogeorgis, E. Nena, N. Papanas, A. Zissimopoulos, A. Voulgaris, M. Xanthoudaki, V. Manolopoulos, M. Froudarakis and P. Steiropoulos*
DOI: 10.2174/1570161115666170529085708




Lipid Metabolism in Patients with End-Stage Renal Disease: A Five Year Follow-up Study

Volume:16   Issue: 3
Pp: 298-305
Magdalena Dusejovska, Barbora Stankova, Marek Vecka*, Jana Rychlíkova, Magdalena Mokrejsova, Ivan Rychlík and Ales Zak
DOI: 10.2174/1570161115666170530104143